Japanese pharmaceutical manufacturer Takeda Pharmaceutical Company, which recently bought Swiss drugmaker Nycomed, is to trim its workforce by 2,800 over the next four years.
Takeda says it will cut 2,100 jobs in Europe and 700 in the US and combine r&d sites or eliminate some subsidiaries, mostly in Europe by the end of 2015.
The company will align Nycomed’s former operation structures and processes with its global headquarters in Japan and the newly defined organisations of the Chief Commercial Officer, which is headquartered in Zurich, Switzerland, and Chief Medical & Scientific Officer, which is headquartered in Deerfield, Illinois and its expanded affiliate network worldwide.
‘The combination of Takeda and Nycomed, which we acquired on 30 September, brought together Takeda’s strong presence in the Japanese and US markets with the legacy Nycomed business infrastructure in Europe and high-growth emerging markets,’ said Yasuchika Hasegawa, president and chief executive of Takeda Pharmaceutical Company.
‘While our combined operations in more than 70 countries are more complementary than overlapping, there are a number of areas where we will need to make changes to ensure efficient and flexible operations moving forward.’
Takeda will also shift its focus from a product portfolio of mature, high selling products to a more diverse portfolio concentrating on new products.
The combined company has a commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.
Takeda says this restructuring will cost an estimated JPY70bn (US$912m; €709m) in total during 2011–2015. During this period, Takeda will achieve cost savings of approximately JPY200bn.
No comments:
Post a Comment